Get access to our best features

Get access to our best features

Published 1 year ago

Thermostable TB Vaccine Found Safe and Immunogenic in Humans

Summary by Ground News

The Access to Advanced Health Institute (AAHI) published the results of a Phase I clinical trial demonstrating the safety and immunogenicity of a new, thermostable vaccine against tuberculosis (TB) The TB vaccine comprises multiple proteins from the causative Mycobacterium tuberculosis(Mtb) bacterium as a fusion protein (designated ID93) combined with a proprietary immune-stimulating adjuvant (called GLA-SE) This single-vial freeze dried formulation can be stored at temperatures of nearly 100 degrees Fahrenheit for months, and is mixed with sterile water just prior to injection.

0 Articles

0 Articles

All

Left

Center

Right

GEN - Genetic Engineering and Biotechnology News…

Thermostable TB Vaccine Found Safe and Immunogenic in Humans

Investigators say Phase I study represents a "major step forward for the field of thermostable lyophilized adjuvant-containing vaccine candidates"

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right

Ground News Article Assistant

Not enough coverage to generate an Article Assistant.

Coverage Details

Total News Sources0

Leaning Left0Leaning Right0Center1Last Updated1 year agoBias Distribution

100% Center

Bias Distribution

100% of the sources are Center

100% Center

GEN - Genetic Engineering and Biotechnology News…

Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics

Stories disproportionately reported by the Left or the Right

Similar News Topics

Trending Topics

Donate Privacy Policy Manage Cookies Terms and Conditions

© 2024 Snapwise Inc.